The moment you hear a cancer diagnosis, the advice starts pouring in. One person recommends turmeric, another green tea, a third suggests ten different supplements that supposedly “destroy cancer cells.” The internet is full of stories from people who claim they were cured thanks to some “superfood,” and the ads promise near-miraculous results.
In a world where you’re already struggling to figure out what to eat, it’s far too easy to be swayed into buying some supplement, some super-mega-incredible food you supposedly need — with no one warning you that it could hurt not just your wallet, but your liver too.
Today we’re talking about so-called “superfoods” — whether they’re really as super as advertised, how they might work alongside your primary treatment, whether that’s radiation, chemotherapy, or immunotherapy. And most importantly — what’s merely assumed to be “super” and what’s actually just very good marketing.
The goal of this article isn’t to convince you to take or avoid any particular supplement. Its goal is to show you what we actually know at this point, what’s still only hypothesized, and where marketing gets ahead of the evidence.
Why do these substances sound so convincing?
There’s a reason curcumin, EGCG, and omega-3 show up so often in scientific publications. All three have measurable biological effects.
Under laboratory conditions, they can suppress inflammatory processes, influence cell signaling, and even slow the growth of some cancer cells. These results are exactly what often turn into sensational headlines like “Scientists discover natural cure for cancer.”
But that’s only the first step.
Observing an effect on cells in a lab doesn’t mean the same effect will show up in the human body. To reach a tumor, a substance has to pass through the digestive system, be absorbed, survive liver metabolism, and reach a sufficient concentration in tissue — all without causing serious side effects.
This is exactly where most promising substances fail.
The gap between “works in a test tube” and “improves patient survival” is enormous. For a substance to cross that gap, it takes years of clinical trials proving not just that it has a biological effect, but that the effect is genuinely beneficial and safe for people.
That’s why so many promising molecules never become medications.
Here’s the full journey a substance has to go through before it can be classified as a drug that actually helps you — something the influencer you follow on Instagram probably won’t tell you.
Curcumin — the most famous “superfood” that didn’t live up to expectations
Curcumin is the main active compound in turmeric — the spice that gives curry its characteristic yellow color. For decades it has been one of the most studied natural molecules in oncology, appearing in hundreds of scientific publications.
The reason is understandable. Under laboratory conditions, curcumin affects numerous processes tied to tumor development — it suppresses inflammatory signaling pathways, alters cell signaling, and under certain conditions can slow the growth of cancer cells.
All of this sounds impressive.
The problem starts when we try to achieve the same results in people.
The big problem is called bioavailability
Curcumin is extremely poorly absorbed.
After oral intake, most of it is broken down or excreted before it ever reaches the bloodstream. This means the concentrations used in lab experiments practically can’t be achieved through ordinary supplement intake.
That’s exactly why so many promising in-vitro results don’t hold up in clinical trials.
This isn’t a lack of research — quite the opposite. Curcumin has been studied intensively. The problem is that human physics and physiology impose limits that a lab experiment simply doesn’t encounter.
A systematic analysis of clinical trials, published in 2024, reaches a clear conclusion: despite numerous attempts to improve absorption, independent studies don’t show convincing evidence that curcumin has a clinically proven benefit in treating malignant disease.
The fix that created a new problem
To overcome curcumin’s poor bioavailability, manufacturers started combining it with piperine — an extract from black pepper.
Piperine genuinely does increase curcumin absorption many times over. At first glance, this looks like the perfect solution.
But higher absorption doesn’t automatically mean higher safety.
The liver pays the price
In recent years, more and more data has accumulated showing that concentrated curcumin supplements can cause drug-induced liver injury.
In 2023, the US-based Drug-Induced Liver Injury Network (DILIN) published a series of ten thoroughly documented cases of liver injury linked to curcumin supplement use. That same year, Australia’s Therapeutic Goods Administration (TGA) reported at least 18 signals of similar adverse reactions, including severe cases and one fatal outcome.
A common thread across many of these cases was the use of high-bioavailability products containing piperine.
This doesn’t mean everyone who takes curcumin will develop liver injury. It does mean, though, that these supplements are far from as harmless as advertising often makes them out to be.
Remember this. When a manufacturer advertises that a formula is absorbed significantly better, that doesn’t just mean a higher potential effect. It also means a higher likelihood of adverse reactions.
During chemotherapy, the risk matters even more
Beyond the potential liver toxicity, curcumin raises another question — the possibility of interacting with anti-cancer drugs.
The liver breaks down a large share of medications with the help of enzymes known as cytochrome P450 (CYP). These enzymes determine how quickly a drug gets processed and how long it stays active in the body.
There’s evidence that curcumin can affect the activity of some of these enzymes, including CYP3A4, CYP1A2, and CYP2C9.
What does that mean in practice?
If a drug starts breaking down more slowly, its concentration in the blood can rise. That doesn’t mean a better anti-tumor effect — it means a higher risk of adverse reactions.
With drugs like paclitaxel, this could increase the risk of peripheral neuropathy, bone marrow suppression, and infections.
With other medications, the situation is reversed. Some drugs first need to be activated in the liver before they start working. Tamoxifen is one of the best-known examples. Although the evidence for a curcumin interaction isn’t conclusive, the existing uncertainty is enough for specialists to recommend caution.
With doxorubicin, the mechanism is likely different, since it isn’t primarily metabolized through CYP enzymes. Even so, there’s evidence that curcumin may affect other mechanisms involved in processing medications.
That’s why most oncology teams recommend not starting concentrated curcumin supplements during active treatment without first discussing it with your doctor.
One clarification is worth making here. This doesn’t apply to turmeric as a spice in food. The amount of curcumin in a serving of curry is incomparably smaller than what’s in a capsule of concentrated extract, and the potential risk is correspondingly different.
EGCG — the active compound in green tea
If curcumin is the most popular “superfood” online, then EGCG (epigallocatechin gallate) is probably the most studied compound in green tea.
The interest in it isn’t accidental. Under laboratory conditions, EGCG shows anti-inflammatory, antioxidant, and anti-tumor properties. It can influence cancer cell growth, change how those cells use energy, and interact with certain immune system mechanisms.
But as we already saw with curcumin, promising lab results aren’t enough. The important question is what studies in humans show.
What do clinical trials show?
So far, there’s no convincing evidence that EGCG treats cancer or improves survival in cancer patients. Some clinical trials, however, have produced interesting results suggesting the substance deserves further study.
For example:
- In patients with bladder cancer, taking 800–1200 mg of EGCG daily led to a dose-dependent reduction in certain tumor tissue biomarkers.
- In men with precancerous prostate changes, 400 mg daily lowered prostate-specific antigen (PSA) levels.
- Several randomized trials showed some reduction in the risk of new colorectal adenomas forming.
- In young women, EGCG was associated with lower mammographic density — a factor linked to breast cancer risk.
These results sound encouraging, but it’s important to put them in the right context.
Most of them measure biomarkers or precancerous changes, not actual clinical outcomes like lower mortality, longer survival, or lower risk of recurrence. This means that, for now, EGCG remains a promising research molecule, not a proven anti-cancer treatment.
What do lab studies show?
Beyond clinical trials, EGCG has also been studied extensively in lab models.
One reason is its ability to influence various cell signaling pathways. For example, it can activate AMPK — an enzyme often called the cell’s “energy sensor.” When this mechanism is activated, the growth and division of some tumor cells can slow down.
Another review, published in 2024 in Frontiers in Immunology, summarizes that EGCG may also affect the tumor microenvironment — for instance, reducing the activity of cells that suppress immune response and supporting the action of cytotoxic T-lymphocytes.
These are interesting mechanisms, but we need to stress something important: most of this data comes from experiments with cells and animal models, not clinical trials in humans.
A mechanism shows how a substance could work. It doesn’t prove that it actually improves patient treatment.
Can nanotechnology solve the problem?
Like curcumin, EGCG has another serious drawback — low bioavailability.
After oral intake, much of the substance breaks down before reaching tissue. That’s why researchers are looking for ways to improve its absorption.
One approach is using nanoparticles.
A study published in 2020 in Scientific Reports showed that so-called nano-EGCG achieved the same anti-tumor effect on lung cancer cells at roughly eight times lower concentration compared to regular EGCG.
That sounds impressive, but there’s an important detail.
The study was conducted entirely on cell lines.
It shows the technology has potential, but doesn’t prove the same effect will be observed in humans. For now, nano forms of EGCG aren’t yet part of standard clinical practice and shouldn’t be assumed to be more effective just because the label says “nano.”
The dose makes the poison
For EGCG, science is fairly unanimous on one point — the risk of liver injury depends on the dose.
According to the European Food Safety Authority (EFSA) and other systematic analyses, at daily intakes above roughly 800 mg of EGCG, the risk of elevated liver enzymes and drug-induced liver injury increases.
For comparison, a cup of green tea contains roughly 50–100 mg of EGCG.
In other words, the problem isn’t green tea itself.
The problem is concentrated extracts, especially when taken on an empty stomach, since absorption — and therefore the risk of toxicity — is higher then.
This is also confirmed by the US National Cancer Institute (NCI), which notes that regular green tea consumption isn’t linked to liver injury, while high-dose extracts can be.
The practical takeaway
If you enjoy green tea, there’s no reason to avoid it during treatment, unless your care team has given specific instructions otherwise. What deserves more caution are concentrated EGCG supplements at high doses. They aren’t a proven anti-cancer treatment, but they can increase the risk of liver toxicity, especially when taken without medical supervision.
Omega-3 — the exception that genuinely has a place in oncology nutrition
Unlike curcumin and EGCG, omega-3 fatty acids (EPA and DHA) aren’t just a promising idea from the lab.
They’re among the few nutrients with real clinical recommendations for certain cancer patients.
It’s important to clarify something from the start, though: this doesn’t mean omega-3 treats cancer. Its benefit is different — it’s mainly tied to maintaining nutritional status and fighting one of the most serious complications of advanced cancer — cachexia.
Why is omega-3 different?
In many patients with advanced cancer, the body gradually starts losing muscle mass and body weight, even when food intake hasn’t dropped significantly. This condition is called cachexia, and it isn’t simply weight loss.
It results from complex metabolic changes, where chronic inflammation speeds up the breakdown of muscle tissue and makes it harder to rebuild.
This is exactly where omega-3 may matter.
EPA and DHA are involved in producing substances that suppress part of the body’s inflammatory processes. This way, they can lower levels of inflammatory markers like IL-6 and C-reactive protein, which play a role in the development of cachexia.
What does ESPEN recommend?
Unlike most supplements, omega-3 appears in the current recommendations from ESPEN (the European Society for Clinical Nutrition and Metabolism).
According to them, in patients with advanced cancer at risk of cachexia, adding EPA and DHA may help support:
- maintaining appetite;
- better food intake;
- preserving lean muscle mass;
- limiting body weight loss.
This is an important distinction. ESPEN doesn’t recommend omega-3 because it “kills cancer cells,” but because it can help the patient tolerate the disease and treatment better.
Does it work for all types of cancer?
No. It’s important to be honest here.
The evidence isn’t equally convincing across all tumor types. For example, a systematic review in patients with advanced pancreatic cancer found no clear advantage of omega-3 over standard high-calorie nutritional supplements. For other cancer types, results look more promising.
The reason is likely that different studies use different doses, different treatment durations, and include patients with different tumor types and disease stages.
So the most accurate conclusion is: omega-3 can be helpful for certain patients, but it isn’t a universal solution for all cancers.
Omega-3 and omega-6 — why the balance matters
It’s often said that omega-3 is “anti-inflammatory” and omega-6 is “pro-inflammatory.” That’s a simplified explanation. Both are necessary for the body.
The difference is that omega-6 more often forms molecules that stimulate the inflammatory response, while omega-3 serves as a source of substances with weaker inflammatory action.
That’s why scientists focus not so much on the amount, but on the ratio between omega-6 and omega-3.
The typical Western diet contains roughly 15–20 times more omega-6 than omega-3. A more balanced ratio — roughly between 1:1 and 4:1 — is thought to be associated with a lower systemic inflammatory burden.
Large observational studies, including data from the UK Biobank, show that a higher omega-6/omega-3 ratio is associated with higher overall mortality and higher cancer mortality.
It’s important, though, not to draw overly bold conclusions. These studies show an association, not proof that a high ratio causes cancer, or that increasing omega-3 alone will prevent recurrence.
The practical takeaway is more modest: a balanced omega-3 intake as part of a varied diet is probably more beneficial than the typical Western diet, which is low in fish and high in processed vegetable oils.
How to increase your omega-3 intake through food
In most cases, food is the better choice — not capsules.
🐟 Baked salmon with a walnut crust
150 g salmon fillet (about 2 g EPA/DHA), 2 tbsp crushed walnuts, 1 tsp olive oil, lemon juice. Bake the salmon at 180°C for about 15–18 minutes, adding the walnuts in the last 5 minutes.
🐟 Sardines on whole-grain toast
1 can of sardines in their own juice (about 1.5 g EPA/DHA), 1 slice of whole-grain bread, sliced tomato. One of the most accessible, omega-3-rich combinations.
🌱 Chia pudding
3 tbsp chia seeds, 200 ml milk, fruit of your choice. Chia contains ALA — the plant form of omega-3. The body can convert some of it into EPA and DHA, though with limited efficiency.
🥗 Green salad with walnuts and flaxseed
Add a handful of walnuts and 1 tbsp freshly ground flaxseed. An easy way to boost your plant-based omega-3 intake in everyday meals.
Is omega-3 safe?
In normal amounts obtained through food, omega-3 is considered safe. With supplements, though, a few clarifications apply.
Clinically used doses are usually 1–2 g of EPA/DHA daily. At intakes above 3 g daily from supplements, the risk of bleeding can increase, especially in people taking anticoagulants or facing upcoming surgery.
That’s why high doses shouldn’t be started without consulting your doctor.
The practical takeaway
Of the three substances covered in this article, omega-3 is the only one with a genuine place in international recommendations for certain cancer patients. That doesn’t mean it’s an anti-cancer drug, though. Its benefit is tied to maintaining nutritional status and limiting cachexia, not to directly destroying tumor cells.
If there’s no specific medical reason for a high-dose supplement, the best approach remains regularly eating fatty fish, nuts, and seeds as part of a balanced diet.
Why does this supplement industry even exist?
When someone faces a serious diagnosis, hope becomes a valuable currency. That’s exactly why the supplement market is so large.
It’s important to know one key difference, though.
Before a drug reaches patients, it has to go through years of clinical trials proving not just that it works, but that its benefits outweigh its risks.
With supplements, the rules are different. In most countries, manufacturers aren’t required to prove clinical efficacy in advance. This means two supplements with similar labels can differ significantly in concentration, purity, and quality.
Of course, this doesn’t mean all supplements are dangerous or useless. It simply means that words like “natural,” “herbal,” or “traditionally used” aren’t proof of effectiveness.
The best question you can ask yourself isn’t: “Does it work in the lab?” It’s: “Has it been proven to help patients like me?”
That’s the question that separates good science from good marketing.
What should you take away from this article?
If you forget almost everything else in a few days, I hope these four conclusions stick:
- Curcumin looks promising in the lab, but at this point there’s no convincing evidence it improves treatment outcomes in humans. Concentrated supplements can interact with anti-cancer drugs and increase the risk of liver injury.
- EGCG is an actively studied compound with interesting lab and early clinical results, but there still isn’t enough evidence that it treats cancer or improves survival. High-dose extracts can be toxic to the liver.
- Omega-3 is the only substance covered here with a place in international recommendations for certain patients — mainly to support nutritional status and limit cachexia, not as an anti-cancer treatment.
- The safest strategy remains balanced nutrition and following your oncologist’s recommendations. If you’re considering any supplement during active treatment, discuss it with your medical team.
In short
| Substance | What does the evidence show? | Practical use | Main risk |
|---|---|---|---|
| Curcumin | Good lab data, but lacking convincing clinical effect | Not routinely recommended as part of treatment | Liver injury and possible drug interactions |
| EGCG (green tea extract) | Promising early clinical results and biomarker changes, but lacking evidence of improved survival | Not a standard part of cancer treatment | Liver toxicity at high extract doses |
| Omega-3 (EPA/DHA) | Supported by clinical studies and ESPEN recommendations for certain patients | May support nutritional status and cachexia | Increased bleeding risk at very high doses and with anticoagulant use |
One last piece of advice
In medicine, miracle solutions are rare.
If any supplement truly cured cancer, it would long since have been included in international oncology guidelines and used in everyday clinical practice.
That doesn’t mean nutrition doesn’t matter, though. Quite the opposite.
Nutrition is one of the most important factors we can actually influence during treatment. But the gap between proven medical care and a well-told marketing story is often enormous.
So don’t look for miracles in a capsule. Look for information grounded in solid scientific evidence, ask your care team questions, and make decisions based on your actual treatment — not on the promises on a label.
This article is for educational purposes and doesn’t replace consultation with your treating physician or dietitian. Supplements, even natural ones, can interact with chemotherapy, radiation therapy, and targeted therapy — always tell your oncology team about any supplement you’re taking or considering.
Sources
- Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis — Naunyn-Schmiedeberg’s Archives of Pharmacology (2024) — pubmed.ncbi.nlm.nih.gov
- Anticancer Molecular Mechanisms of Curcuminoids: An Updated Review of Clinical Trials — Food Science & Nutrition (2026) — onlinelibrary.wiley.com
- Curcumin and Cancer (PDQ®) — National Cancer Institute — cancer.gov
- Halegoua-DeMarzio, D. et al. Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the DILIN. American Journal of Medicine (2023) — pmc.ncbi.nlm.nih.gov
- TGA — Medicines containing turmeric or curcumin: risk of liver injury (safety alert, 2023) — tga.gov.au
- Drug-Induced Liver Injury Secondary to Turmeric Supplement Containing Piperine: A Case Report — Cureus (2025) — cureus.com
- Green Tea — LiverTox, NIH — ncbi.nlm.nih.gov
- The safety of green tea and green tea extract consumption in adults — systematic review — sciencedirect.com
- Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins — pmc.ncbi.nlm.nih.gov
- A Prospective Interventional Study on Fish Oil-Enriched Oral Nutritional Supplement in Malnourished Older Cancer Patients — Nutrients (2025), citing the current ESPEN guidelines — mdpi.com
- Eicosapentaenoic acid (EPA) for the treatment of cancer cachexia — Cochrane systematic review — pmc.ncbi.nlm.nih.gov
- A dose–response meta-analysis of omega-3 supplementation on body weight in cancer cachexia — Clinical Nutrition (2024) — sciencedirect.com
- Chen, B.H. et al. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Scientific Reports (2020) — nature.com
- Li, D. et al. The roles of epigallocatechin gallate in the tumor microenvironment, metabolic reprogramming, and immunotherapy. Frontiers in Immunology (2024) — frontiersin.org